Huadong Medicine
HD Medicine, or Huadong Medicine Co., Ltd., is a Hangzhou-based pharmaceutical company registered on the Shenzhen Stock Exchange since January 27, 2000. It has a listed share capital of 380,000,000 renminbi and a market capitalization of 126,323,040 renminbi. It is the largest pharmaceutical company in Zhejiang and the leading immunosuppressant manufacturer in China.
In June 2025, the company received approval to commence clinical trials for Roflumilast Foam, targeting dermatological conditions.